

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 October 2021 (28.10.2021)



(10) International Publication Number
WO 2021/214270 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) C12N 15/87 (2006.01)
C12N 5/0783 (2010.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/EP2021/060622

(22) International Filing Date:

23 April 2021 (23.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/014,831 24 April 2020 (24.04.2020) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 151 85
Södertälje (SE).

(72) Inventors: **MOODY, Gordon**; AstraZeneca Pharmaceuti-
cals LP, 1800 Concord Pike, P.O. Box 15437, Wilmington,
Delaware 19850-5437 (US). **GIARDINO-TORCHIA,**
Maria, Letizia; AstraZeneca Pharmaceuticals LP, 1800
Concord Pike, P.O. Box 15437, Wilmington, Delaware
19850-5437 (US). **OVERSTREET, Michael, Glen**; As-
traZeneca Pharmaceuticals LP, 1800 Concord Pike, P.O.
Box 15437, Wilmington, Delaware 19850-5437 (US). **GIL-**
BRETH, Ryan; AstraZeneca Pharmaceuticals LP, 1800

Concord Pike, P.O. Box 15437, Wilmington, Delaware
19850-5437 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPER-**
TY; Milstein Building Granta Park, Cambridge Cam-
bridgeshire CB21 6GH (GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS

(57) Abstract: This disclosure relates to compositions and methods for treating cancer
using armored chimeric antigen receptor cells.

B

TGFβRIIDN "armored" CAR T-cell




Fig. 3

WO 2021/214270 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*